Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) EBIT (2023 - 2025)

Mangoceuticals' EBIT history spans 3 years, with the latest figure at -$367739.0 for Q4 2025.

  • On a quarterly basis, EBIT fell 108.23% to -$367739.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$18.0 million, a 886.17% decrease, with the full-year FY2025 number at -$18.0 million, down 886.17% from a year prior.
  • EBIT hit -$367739.0 in Q4 2025 for Mangoceuticals, up from -$7.5 million in the prior quarter.
  • Over the last five years, EBIT for MGRX hit a ceiling of $4.5 million in Q4 2024 and a floor of -$7.5 million in Q3 2025.
  • Historically, EBIT has averaged -$2.4 million across 3 years, with a median of -$2.3 million in 2023.
  • Biggest five-year swings in EBIT: soared 273.9% in 2024 and later tumbled 329.04% in 2025.
  • Tracing MGRX's EBIT over 3 years: stood at -$2.6 million in 2023, then soared by 273.9% to $4.5 million in 2024, then plummeted by 108.23% to -$367739.0 in 2025.
  • Business Quant data shows EBIT for MGRX at -$367739.0 in Q4 2025, -$7.5 million in Q3 2025, and -$5.3 million in Q2 2025.